Here are three findings:
1. In 2013, the market was valued at $1.8 billion.
2. North America dominates the global spinal biologics market, with the U.S. leading the pack.
3. Key companies in the market include DePuy Synthes, NuVasive and Orthofix International.
More articles on biologics:
Anika Therapeutics resumes distribution of cartilage regeneration treatments
AlloSource earns laser etching patent: 3 notes
4 things to know about Bio2 Technologies
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
